New Amsterdam Pharma CO N.V. NAMS
We take great care to ensure that the data presented and summarized in this overview for NewAmsterdam Pharma Co N.V. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in NAMS
Top Purchases
Top Sells
About NAMS
Insider Transactions at NAMS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 15
2025
|
Douglas F Kling Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
100,000
-35.42%
|
-
|
|
Apr 15
2025
|
Douglas F Kling Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+40.98%
|
$1,000,000
$10.0 P/Share
|
|
Apr 15
2025
|
Adele M. Gulfo |
BUY
Grant, award, or other acquisition
|
Direct |
10,860
+50.0%
|
-
|
|
Apr 14
2025
|
Louis G Lange |
BUY
Exercise of conversion of derivative security
|
Indirect |
69
+0.25%
|
-
|
|
Mar 26
2025
|
James N Topper |
BUY
Open market or private purchase
|
Indirect |
1,135
+0.04%
|
$24,970
$22.49 P/Share
|
|
Mar 26
2025
|
Louise Frederika Kooij Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,269
+26.22%
|
-
|
|
Mar 26
2025
|
Johannes Jacob Pieter Kastelein Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
45,481
+36.4%
|
-
|
|
Mar 26
2025
|
Johannes Jacob Pieter Kastelein Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
19,302
+10.23%
|
-
|
|
Mar 26
2025
|
Louis G Lange |
BUY
Exercise of conversion of derivative security
|
Direct |
3,102
+23.56%
|
-
|
|
Mar 26
2025
|
Michael H. Davidson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
12,258
-3.04%
|
-
|
|
Mar 26
2025
|
Michael H. Davidson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
38,394
+8.7%
|
-
|
|
Mar 26
2025
|
Michael H. Davidson Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,992
+7.84%
|
-
|
|
Mar 26
2025
|
Douglas F Kling Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
16,539
-27.32%
|
-
|
|
Mar 26
2025
|
Douglas F Kling Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,539
+21.46%
|
-
|
|
Mar 24
2025
|
Johannes Jacob Pieter Kastelein Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
150,000
+50.0%
|
-
|
|
Mar 17
2025
|
Douglas F Kling Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
100,000
-69.44%
|
-
|
|
Mar 17
2025
|
Douglas F Kling Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+23.82%
|
$1,000,000
$10.0 P/Share
|
|
Mar 04
2025
|
James N Topper |
BUY
Open market or private purchase
|
Indirect |
4,005
+0.13%
|
$84,105
$21.02 P/Share
|
|
Mar 04
2025
|
Louise Frederika Kooij Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
150,000
-90.91%
|
$3,000,000
$20.37 P/Share
|
|
Mar 04
2025
|
Louise Frederika Kooij Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
150,000
+47.62%
|
-
|
Last 12 Months Summary
Buy / Acquisition
1.44M
Shares
From
22
Insiders
| Grant, award, or other acquisition | 407K shares |
|---|---|
| Open market or private purchase | 16.2K shares |
| Exercise of conversion of derivative security | 1.02M shares |
Sell / Disposition
1.96M
Shares
From
5
Insiders
| Open market or private sale | 1.96M shares |
|---|